While the initial successes of RLT have been centered on prostate-specific membrane antigen (PSMA) and somatostatin receptors, the US market is rapidly expanding into new therapeutic areas. Researchers are identifying a vast array of new targets, such as Fibroblast Activation Protein (FAP), which is expressed in the stroma of many different types of solid tumors, including breast, pancreatic, and lung cancers. This expansion suggests that radioligand therapy could eventually become a "pan-cancer" modality, applicable across a wide spectrum of oncology.

The US Radioligand Therapy (RLT) Market is seeing a significant increase in clinical trials targeting "hard-to-treat" cancers. The development of new ligands—including small molecules, peptides, and even antibodies—is allowing for a more diverse range of radioactive payloads. Alpha-emitting therapies, in particular, are gaining traction due to their high energy and short path length, which can induce double-stranded DNA breaks in cancer cells that are resistant to standard beta-radiation. This diversification of the therapeutic pipeline is attracting massive venture capital and partnership interest from traditional large-cap pharmaceutical firms.